PRODH

Across TCGA pan-cancer cohorts, PRODH mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRODH data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRODH mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRODH expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where PRODH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	1.000	0.770	.007	20	view →
CCRCC	OS	Tertile	II,III,IV	0.951	0.758	.008	16	view →
GBM	DFS	Tertile	All	0.254	0.458	.002	11	view →
UCEC	DFS	Median	All	1.000	0.935	.020	6	view →
PDAC	DFS	Median	All	0.555	0.327	.049	2	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRODH–LUAD (OS)

Open the LUAD breakdown →